Japan: Astellas targets creation of world class ophthalmology company through Iveric Bio acquisition

Astellas Pharma, a Tokyo-listed pharmaceutical company, has entered into an agreement to acquire US-based Iveric Bio, a biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases. Astellas through Berry Merger Sub, a wholly-owned subsidiary of Astellas US Holding, has agreed to acquire 100% of the outstanding Iveric Bio shares for…

You must be a HMI Subscriber to view this content.

Subscribe Now »